清肝利湿颗粒联合恩替卡韦治疗肝胆湿热型乙肝肝硬化患者的临床效果观察  

Clinical Observation of Qinggan Lishi Granule Combined with Entecavir in the Treatment of Patients with Liver-Gallbladder Damp-Heat Type Hepatitis B Cirrhosis

作　　者：张雪娇 ZHANG Xuejiao(Department of Gastroenterology,Chifeng City Hospital,Chifeng 024000,China)

机构地区：[1]内蒙古自治区赤峰市医院消化内科,内蒙古自治区赤峰024000

出　　处：《中国伤残医学》2025年第1期83-87,共5页Chinese Journal of Trauma and Disability Medicine

摘　　要：目的:探讨清肝利湿颗粒联合恩替卡韦治疗肝胆湿热型乙肝肝硬化患者的临床效果。方法:选择2021年1月—2023年1月赤峰市医院收治的82例肝胆湿热型乙肝肝硬化患者为研究对象,采用随机数字表法将其分为对照组和研究组,各41例。对照组采用恩替卡韦治疗,研究组采用恩替卡韦联合清肝利湿颗粒治疗。两组均治疗6个月。对比两组治疗总有效率、生化指标、影像学特征、乙型肝炎病毒脱氧核糖核酸(HBV-DNA)转阴情况和不良反应发生情况。结果:研究组治疗总有效率为97.56%,高于对照组的68.29%,差异有统计学意义(P<0.05)。治疗1个月后,研究组的丙氨酸转氨酶、天冬氨酸转氨酶、总胆红素水平均低于对照组,差异均有统计学意义(P<0.05)。治疗1个月后,研究组的门静脉最大流速、脾静脉最大流速均慢于对照组,门静脉内径、脾静脉内径均小于对照组,差异均有统计学意义(P<0.05)。研究组HBV-DNA转阴率为97.56%,高于对照组的80.49%;研究组不良反应发生率为4.88%,低于对照组的24.39%,差异均有统计学意义(P<0.05)。结论:采用清肝利湿颗粒联合恩替卡韦治疗肝胆湿热型乙肝肝硬化患者,有利于提高治疗效果,改善生化和影像学指标,提高HBV-DNA转阴率,降低不良反应发生率。Objective:To explore the clinical efficacy of Qinggan Lishi Granule combined with Entecavir in the treatment of patients with hepatitis B cirrhosis with liver-gallbladder damp-heat.Methods:A total of 82 patients with liver cirrhosis due to damp-heat in liver-gallbladder admitted to Chifeng City Hospital from January 2021 to January2023 were selected as the study objects,and were divided into a control group and a study group by random number table method,with 41 cases in each group.The control group was treated with Entecavir,while the study group was treated with Entecavir and Qinggan Lishi Granule.Both groups were treated for 6 months The total effective rate of treatment,biochemical indexes,imaging characteristics,Hepatitis B virus deoxyribonucleic acid(HBV-DNA)conversion and adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the study group was 97.56%,which was higher than 68.29%in the control group,with statistical significance(P<0.05).After 1 month of treatment,the alanine aminotransferase,aspartate aminotransferase,total bilirubin levels in the study group were lower than those in the control group,with statistical significance.(P<0.05).After 1 month of treatment,the maximum flow rate of portal vein and splenic vein in the study group were slower than those in the control group,the inner diameter of portal vein and spleen vein were smaller than those of control group,with statistical significance(P<0.05).The negative conversion rate of HBV-DNA in the study group was 97.56%,which was higher than 80.49%in the control group,the incidence of adverse reactions in the study group was 4.88%,which was lower than 24.39%in the control group,with statistical significance(P<0.05).Conclusion:The use of Qinggan Lishi Granule combined with Entecavir in the treatment of patients with liver-gallbladder damp-heat hepatitis B cirrhosis is conducive to improving the treatment effect,improving biochemical and imaging indicators,increasing the rate of HBV-DNA conversion to ne

关 键 词：肝胆湿热型 乙肝肝硬化 清肝利湿颗粒 恩替卡韦 临床疗效 不良反应 

分 类 号：R575[医药卫生—消化系统]